China Antibody Drug Conjugates Market Size & Outlook
Related Markets
China antibody drug conjugates market highlights
- The China antibody drug conjugates market generated a revenue of USD 747.6 million in 2024 and is expected to reach USD 2,297.3 million by 2033.
- The China market is expected to grow at a CAGR of 13.3% from 2025 to 2033.
- In terms of segment, breast cancer was the largest revenue generating application in 2024.
- Urothelial Carcinoma is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2024 | USD 747.6 million |
| Market revenue in 2033 | USD 2,297.3 million |
| Growth rate | 13.3% (CAGR from 2025 to 2033) |
| Largest segment | Breast cancer |
| Fastest growing segment | Urothelial Carcinoma |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Blood Cancer, Urothelial Carcinoma, Ovarian Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, China accounted for 6.1% of the global antibody drug conjugates market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,442.0 million by 2033.
Breast cancer was the largest segment with a revenue share of 40.96% in 2024. Horizon Databook has segmented the China antibody drug conjugates market based on breast cancer, blood cancer, urothelial carcinoma, ovarian cancer covering the revenue growth of each sub-segment from 2021 to 2033.
China’s ADC market is expected to grow at a significant rate over the forecast period, owing to increase in availability and focus on development of ADC therapies. Chinese companies such as Reme Gen Co., Ltd., Bio-Thera Solutions, and 3SBio Group are making significant investments in ADC drug development. Reme Gen Co., Ltd.’s lead ADC drug candidate, disitamab vedotin (RC48), was the first to undergo human studies in China.
The company has already filed for NDA of this product with the NMPA for treatment of stomach cancer. The drug was granted priority review in August 2020. In 2018, Bio-Thera Solutions’ lead ADC candidate, BAT8001, entered phase 3 trial for treatment of advanced HER2-positive breast cancer.
It skipped phase 2 clinical trials and surpassed RC48 by becoming the first ADC to have entered Phase 3 studies in China. The development and subsequent approval for ADC drugs by local players is expected to be one of the major factors driving the ADC market in China.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| ADC Therapeutics SA | View profile | 274 | Route de la Corniche 3B, Biopole, Epalinges, Switzerland, 1066 | https://www.adctherapeutics.com |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | https://india-consumer.gsk.com/ |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
China antibody drug conjugates market size, by application, 2021-2033 (US$M)
China Antibody Drug Conjugates Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
